References
- Bismuth C, Baud F, Dally S. Standardized prognosis evaluation in acute toxicology: its benefit in colchicine, paraquat, and digitalis poisoning. J Toxicol Clin Exp 1986; 6:33–38.
- Borron SW, Scherrmann JM, Baud FJ. Markedly altered colchicine kinetics in a fatal intoxication: examination of contributing factors. Hum Exp Toxicol 1996; 15:885–890.
- Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ. Colchicine biotransformation by human liver microsomes. Indentification of CYP3A4 as the major isoform responsible for colchicine demethylation. Biochem Pharmacol 1997; 53:111–116.
- Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum 2009; 38:411–419.
- Tang W. The metabolism of diclofenac. Enzymology and toxicology perspectives. Curr Drug Metab 2003; 4:319–329.
- Park JE, Kim KB, Bae SK, Moon BS, Liu KH, Shin JG. Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Xenobiotica 2008; 38:1240–1251.
- Holtzman CW, Wiggins BS, Spinler SA. Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 2006; 26:1601–1607.
- Wilbur K, Makowsky M. Colchicine myotoxicity: case reports and literature review. Pharmacotherapy 2004; 24:1784–1792.
- Tufan A, Dede DS, Cavus S, Altintas ND, Iskit AB, Topeli A. Rhabdomyolysis in a patient treated with colchicine and atorvastatin. Ann Pharmacother 2006; 40:1466–1469.
- Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97:52C–60C.
- Francis L, Bonilla E, Soforo E, Neupane H, Nakhla H, Fuller C, Perl A. Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin. Clin Rheumatol 2008; 1:129–131.
- Vasile B, Rasulo F, Candiani A, Latronico N. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med 2003; 29:1417–1425.
- Pugliese A, Beltramo T, Torre D. Reye’s and Reye’s-like syndrome. Cell Biochem Funct 2008; 26:741–746.